The Chinese government is investigating four senior executives of GlaxoSmithKline (GSK) in China for allegedly bribing officials and physicians to boost GSK drug sales, funnelling the money through travel agencies. The executives are suspected of giving 3 billion renminbi (US$489 million) in bribes since 2007, Chinese officials said last week.
展开▼
